{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:30:23Z","timestamp":1792150223990,"version":"4.4.0"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:p>This report outlines the case of a 9-year-old girl with severe anti\u2013nuclear matrix protein 2 antibody\u2013positive juvenile dermatomyositis presenting with disease refractory to multiple traditional therapies. Treatment with an experimental monoclonal antibody inhibiting interferon beta (IFN\u03b2) resulted in the rapid resolution of her muscle weakness and cutaneous and gastrointestinal ulcers. This case highlights the potential benefit of inhibiting IFN\u03b2 in the management of recalcitrant juvenile dermatomyositis.<\/jats:p>","DOI":"10.1542\/peds.2024-067481","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:18:59Z","timestamp":1742501939000},"source":"Crossref","is-referenced-by-count":8,"title":["Monoclonal antibody targeting IFN\u03b2 for the treatment of NXP2-positive ulcerative juvenile dermatomyositis"],"prefix":"10.1542","volume":"155","author":[{"given":"Justina","family":"Guirguis","sequence":"first","affiliation":[{"name":"1The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York"},{"name":"2Division of Pediatric Dermatology, McGill University Health Centre, Montreal Children\u2019s Hospital, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"1The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ann Vleugels","sequence":"additional","affiliation":[{"name":"3Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"4Division of Immunology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"5Department of Neurology, Brigham and Women\u2019s Hospital Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kim","sequence":"additional","affiliation":[{"name":"6Juvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Kahn","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Division of Pediatric Rheumatology, Hassenfeld Children\u2019s Hospital at NYU Langone Health, NYU Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Oza","sequence":"additional","affiliation":[{"name":"1The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"2","key":"2026100510432021600_r1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2026100510432021600_r2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.11122","article-title":"US incidence of juvenile dermatomyositis, 1995\u20131998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry","volume":"49","author":"Mendez","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"3","key":"2026100510432021600_r3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acr.22142","article-title":"Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"66","author":"Robinson","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"2026100510432021600_r4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/rheumatology\/keq261","article-title":"A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10\u00a0years\u2019 experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies [published correction appears in Rheumatology (Oxford). 2011;50(3):635]","volume":"50","author":"Martin","year":"2011","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"2026100510432021600_r5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"2026100510432021600_r6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol."},{"issue":"9","key":"2026100510432021600_r7","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3899\/jrheum.090953","article-title":"Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey","volume":"37","author":"Stringer","year":"2010","journal-title":"J Rheumatol."},{"issue":"2","key":"2026100510432021600_r8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"5","key":"2026100510432021600_r9","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol."},{"issue":"5","key":"2026100510432021600_r10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol."},{"issue":"5","key":"2026100510432021600_r11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon \u03b2 is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"2026100510432021600_r12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000816","article-title":"Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy","volume":"33","author":"Kim","year":"2021","journal-title":"Curr Opin Rheumatol."},{"issue":"4","key":"2026100510432021600_r13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"2026100510432021600_r14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.rdc.2021.07.003","article-title":"Updates on juvenile dermatomyositis from the last decade: classification to outcomes","volume":"47","author":"Kim","year":"2021","journal-title":"Rheum Dis Clin North Am."},{"issue":"1","key":"2026100510432021600_r15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12969-020-00486-x","article-title":"Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature","volume":"19","author":"Xu","year":"2021","journal-title":"Pediatr Rheumatol Online J."},{"issue":"1","key":"2026100510432021600_r16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12969-020-00492-z","article-title":"Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children","volume":"19","author":"Wang","year":"2021","journal-title":"Pediatr Rheumatol Online J."},{"issue":"6","key":"2026100510432021600_r17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"2026100510432021600_r18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther."},{"issue":"3","key":"2026100510432021600_r19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cpdd.887","article-title":"Safety, tolerability, and pharmacokinetics of PF-06823859, an anti-interferon \u03b2 monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study","volume":"10","author":"Neelakantan","year":"2021","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"suppl 9","key":"2026100510432021600_r20","article-title":"Rapid onset of response in adult dermatomyositis patients receiving anti-interferon \u03b2 (PF-06823859): results of a phase 2, double-blind, randomized, placebo-controlled study [abstract]","volume":"75","author":"Aggarwal","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"2026100510432021600_r21","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/annrheumdis-2023-eular.3230","article-title":"POS1207 efficacy and safety of anti-IFN\u03b2-specific monoclonal antibody, PF-06823859, on myositis: phase 2 study in patients with moderate-to-severe dermatomyositis","volume":"82","author":"Aggarwal","year":"2023","journal-title":"Ann Rheum Dis."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-067481\/1792916\/pediatrics.2024067481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-067481\/1792916\/pediatrics.2024067481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:43:28Z","timestamp":1791211408000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/155\/4\/e2024067481\/201295\/Monoclonal-antibody-targeting-IFN-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,3,21]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2024-067481","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"e2024067481"}}